Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$25.56M$25.56M−59.9% vs Q3 2017 Net Income-$27.85M-$27.85MN/M vs Q3 2017 EPS Diluted-$0.19-$0.19N/M vs Q3 2017 Gross Profit$5,643,000+7.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$18,927,000N/M Free Cash Flowderived-$19,260,000N/M Margins · derivedGross margin22.1%+13.8 pt vs Q3 2017
Operating margin-99.7%−112.4 pt vs Q3 2017
Net margin-109.0%−113.3 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 6, 2018 · 37 d after period end